Skip to content
HowShorted

INOVIO PHARMACEUTICALS, INC. short interest in 2021

In 2021, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 33.10% of shares outstanding on 15 Jan 2021 to 22.00% on 31 Dec 2021, a change of -11.10 percentage points. The year's high was 33.10% on 15 Jan 2021 and its low 20.24% on 13 Aug 2021, averaging 23.55% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.06 days on 29 Oct 2021. Full history: INOVIO PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INOVIO PHARMACEUTICALS, INC. in 2021

2021 in figures

Start of year
33.10% (15 Jan 2021)
End of year
22.00% (31 Dec 2021)
Change
-11.10 pp
High
33.10% (15 Jan 2021)
Low
20.24% (13 Aug 2021)
Average
23.55%
Highest days to cover
18.06 (29 Oct 2021)
SEC filings marked
6

Every report in 2021

INOVIO PHARMACEUTICALS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202133.10%7.47
29 Jan 202125.57%2.43results (8-K)
12 Feb 202125.43%1.79
26 Feb 202124.19%4.23
15 Mar 202127.53%5.0510-K filed, results (8-K)
31 Mar 202126.32%8.83
15 Apr 202124.77%9.39
30 Apr 202126.23%4.70
14 May 202126.97%7.2810-Q filed
28 May 202124.53%12.24
15 Jun 202122.51%6.96
30 Jun 202121.47%8.93
15 Jul 202121.91%12.37
30 Jul 202120.90%12.71
13 Aug 202120.24%6.2010-Q filed
31 Aug 202120.70%9.05
15 Sep 202121.13%11.09
30 Sep 202121.49%13.13
15 Oct 202121.87%14.86
29 Oct 202121.94%18.06
15 Nov 202121.83%9.6710-Q filed
30 Nov 202121.75%10.48
15 Dec 202120.82%9.78
31 Dec 202122.00%8.15

See also: INOVIO PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.